Polycystic Ovary Syndrome (PCOS) is emerging as a major women's health concern in India due to its rising prevalence, ...

U.S. FDA Fast Track designation granted to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for the ...

1. Glucagon-like peptide-1 receptor agonists (GLP-1RA) in combination with progestins are significantly more effective at reducing endometrial cancer (EC) risk compared to progestins alone in female ...

GLP-1RA therapy plus progestin therapy is associated with a significantly reduced endometrial cancer risk (HR, 0.34; 95% CI, 0.27-0.44) compared to progestin therapy only. For patients with ...

About The Study: In this cohort study of women with benign uterine pathology or endometrial hyperplasia, combined glucagon-like peptide-1 receptor agonist (GLP-1RA) and progestin was associated with ...

Improved patient care is needed to reduce cancer risk among women with a condition that causes excessive thickening of the womb lining, research shows. Tamoxifen treatment is associated with increased ...

ABSTRACT: A total of 157 patients were included in this study, comprising 147 with simple Endometrial Hyperplasia (EH) and 10 with complex EH. All patients treated cyclically with progestin or ...

1 Department of Obstetrics & Gynecology, Gujo City Hospital, Gujo City, Japan. 2 Department of Obstetrics & Gynecology, Central Japan International Medical Center, Minokamo City, Japan. 3 Department ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing ...